These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 15234426

  • 1. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.
    L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC.
    J Am Coll Cardiol; 2004 Jul 07; 44(1):159-64. PubMed ID: 15234426
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation.
    Lip GY, Frison L, Grind M.
    J Intern Med; 2007 Jun 07; 261(6):577-86. PubMed ID: 17547713
    [Abstract] [Full Text] [Related]

  • 3. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.
    Arch Intern Med; 2005 Apr 25; 165(8):936-46. PubMed ID: 15851647
    [Abstract] [Full Text] [Related]

  • 4. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB.
    Circ Arrhythm Electrophysiol; 2008 Dec 25; 1(5):337-43. PubMed ID: 19808428
    [Abstract] [Full Text] [Related]

  • 5. Retrospective longitudinal cohort study comparing the effects of angiotensin-converting enzyme inhibitors and long-acting calcium channel blockers on total and cardiovascular mortality in patients with hypertension.
    Tardif JC, Ducharme A, Yu H, Wogen J, Guertin MC.
    Clin Ther; 2004 Jul 25; 26(7):1073-83. PubMed ID: 15336472
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB.
    J Am Coll Cardiol; 2005 Mar 01; 45(5):712-9. PubMed ID: 15734615
    [Abstract] [Full Text] [Related]

  • 7. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation.
    Nieuwlaat R, Eurlings LW, Cleland JG, Cobbe SM, Vardas PE, Capucci A, López-Sendòn JL, Meeder JG, Pinto YM, Crijns HJ.
    J Am Coll Cardiol; 2009 May 05; 53(18):1690-8. PubMed ID: 19406345
    [Abstract] [Full Text] [Related]

  • 8. Renin-angiotensin-system modulators and the incidence of atrial fibrillation following hospitalization for coronary artery disease.
    Singh JP, Kulik A, Levin R, Ellinor PT, Ruskin J, Avorn J, Choudhry NK.
    Europace; 2012 Sep 05; 14(9):1287-93. PubMed ID: 22539600
    [Abstract] [Full Text] [Related]

  • 9. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients.
    Genovesi S, Vincenti A, Rossi E, Pogliani D, Acquistapace I, Stella A, Valsecchi MG.
    Am J Kidney Dis; 2008 Feb 05; 51(2):255-62. PubMed ID: 18215703
    [Abstract] [Full Text] [Related]

  • 10. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.
    Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA, VALUE Trial Group.
    J Hypertens; 2008 Mar 05; 26(3):403-11. PubMed ID: 18300848
    [Abstract] [Full Text] [Related]

  • 11. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.
    Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G, BENEDICT Study Group.
    J Am Soc Nephrol; 2006 Dec 05; 17(12):3472-81. PubMed ID: 17082240
    [Abstract] [Full Text] [Related]

  • 12. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
    Richter B, Derntl M, Marx M, Lercher P, Gössinger HD.
    Am Heart J; 2007 Jan 05; 153(1):113-9. PubMed ID: 17174648
    [Abstract] [Full Text] [Related]

  • 13. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T, Sakurai M, Sato T, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, Watanabe E, Ogawa S, J-RHYTHM II Investigators.
    Europace; 2011 Apr 05; 13(4):473-9. PubMed ID: 21148662
    [Abstract] [Full Text] [Related]

  • 14. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.
    Salehian O, Healey J, Stambler B, Alnemer K, Almerri K, Grover J, Bata I, Mann J, Matthew J, Pogue J, Yusuf S, Dagenais G, Lonn E, HOPE Investigators.
    Am Heart J; 2007 Sep 05; 154(3):448-53. PubMed ID: 17719288
    [Abstract] [Full Text] [Related]

  • 15. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.
    Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A.
    Circulation; 2003 Jun 17; 107(23):2926-31. PubMed ID: 12771010
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
    Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R.
    J Am Soc Nephrol; 2006 Mar 17; 17(3):889-99. PubMed ID: 16481415
    [Abstract] [Full Text] [Related]

  • 17. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study.
    Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR.
    Ann Intern Med; 2010 Jan 19; 152(2):78-84. PubMed ID: 20083826
    [Abstract] [Full Text] [Related]

  • 18. Obesity and risk of new-onset atrial fibrillation after cardiac surgery.
    Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah AS, Habib RH.
    Circulation; 2005 Nov 22; 112(21):3247-55. PubMed ID: 16286585
    [Abstract] [Full Text] [Related]

  • 19. Atrial fibrillation during acute myocardial infarction: association with all-cause mortality and sudden death after 7-year of follow-up.
    Berton G, Cordiano R, Cucchini F, Cavuto F, Pellegrinet M, Palatini P.
    Int J Clin Pract; 2009 May 22; 63(5):712-21. PubMed ID: 19392921
    [Abstract] [Full Text] [Related]

  • 20. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation.
    Anand K, Mooss AN, Hee TT, Mohiuddin SM.
    Am Heart J; 2006 Aug 22; 152(2):217-22. PubMed ID: 16875900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.